OverviewChartProfileKey statisticsFinancialsNews
Derivatives
TraderScreen

VIATRIS INC. O.N./  US92556V1061  /

München
31/05/2024  08:04:15 Chg. +0.024 Volume Bid21:59:31 Ask21:59:31 Market Capitalization Dividend Y. P/E Ratio
9.582EUR +0.25% 0
Turnover: 0.000		 -Bid Size: - -Ask Size: - 11.64 bill.EUR - -
GlobeNewswire 10/05 Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
GlobeNewswire 06/05 Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting
GlobeNewswire 03/05 Ocuphire Pharma to Present at the Aegis Virtual Conference
GlobeNewswire 01/05 NeurologyLive® and CMSC Announce the 3rd Annual Class of Inductees
GlobeNewswire 22/04 Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting
GlobeNewswire 11/04 First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS...
GlobeNewswire 01/04 Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) b...
GlobeNewswire 20/03 Lifecore Biomedical Concludes Strategic Evaluation Process, Announces Management Succession and Boar...
GlobeNewswire 08/03 Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corpo...
TeleTrader 28/02 US closes lower after GDP data, ahead of earnings
GlobeNewswire 28/02 Idorsia and Viatris enter into a significant global research and development collaboration
GlobeNewswire 23/02 Ocuphire Pharma to Present in the BIO CEO & Investor Conference
GlobeNewswire 15/02 Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 14/02 ACTG Announces Launch of Clinical Trial Evaluating Drug-Drug Interaction in Shortened Tuberculosis R...
GlobeNewswire 14/02 Ocuphire Pharma Strengthens Leadership Team with Key Appointments
GlobeNewswire 05/02 Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degener...
GlobeNewswire 02/02 Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
GlobeNewswire 24/01 Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 04/01 Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of...
GlobeNewswire 02/01 VIATRIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Viatris Inc. on Behalf of Long-Term Stoc...
GlobeNewswire 30/11/2023 Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII
GlobeNewswire 30/11/2023 Biocon Biologics Successfully Completes Integration of Viatris’ Biosimilar Business in 31 Countries ...
GlobeNewswire 27/11/2023 Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 27/11/2023 Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer
GlobeNewswire 13/11/2023 Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update